Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'S-MEPHENYTOIN' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 292 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Masimirembwa, CM; Thompson, R; Andersson, TB
      In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery

      COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
    2. Dubuc, MC; Hamel, C; Caubet, MS; Brazier, JL
      A rapid HPLC-DAD method for separation and determination of omeprazole extracted from human plasma

      JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
    3. Dai, D; Zeldin, DC; Blaisdell, JA; Chanas, B; Coulter, SJ; Ghanayem, BI; Goldstein, JA
      Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid

      PHARMACOGENETICS
    4. Furuta, T; Shirai, N; Takashima, M; Xiao, F; Hanai, H; Nakagawa, K; Sugimura, H; Ohashi, K; Ishizaki, T
      Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

      PHARMACOGENETICS
    5. Griese, EU; Ilett, KF; Kitteringham, NR; Eichelbaum, M; Powell, H; Spargo, RM; LeSouef, PN; Musk, AW; Minchin, RF
      Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in Aborigines from Western Australia

      PHARMACOGENETICS
    6. Gerson, LB; Triadafilopoulos, G
      Proton pump inhibitors and their drug interactions: an evidence-based approach

      EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
    7. Yamada, S; Onda, M; Kato, S; Matsuda, N; Matsuhisa, T; Yamada, N; Miki, M; Matsukura, N
      Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations

      JOURNAL OF GASTROENTEROLOGY
    8. Sakai, T; Aoyama, N; Kita, T; Sakaeda, T; Nishiguchi, K; Nishitora, Y; Hohda, T; Sirasaka, D; Tamura, T; Tanigawara, Y; Kasuga, M; Okumura, K
      CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects

      PHARMACEUTICAL RESEARCH
    9. Kita, T; Tanigawara, Y; Aoyama, N; Hohda, T; Saijoh, Y; Komada, F; Sakaeda, T; Okumura, K; Sakai, T; Kasuga, M
      CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability

      PHARMACEUTICAL RESEARCH
    10. Xie, HG; Kim, RB; Wood, AJJ; Stein, CM
      Molecular basis of ethnic differences in drug disposition and response

      ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
    11. Goldstein, JA
      Clinical relevance of genetic polymorphisms in the human CYP2C subfamily

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    12. Roh, HK; Chung, JY; Oh, DY; Park, CS; Svensson, JO; Dahl, ML; Bertilsson, L
      Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    13. Yokono, A; Morita, S; Someya, T; Hirokane, G; Okawa, M; Shimoda, K
      The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    14. Teh, LK; Ismail, R; Yusoff, R; Hussein, A; Isa, MN; Rahman, ARA
      Heterogeneity of the CYP2D6 gene among Malays in Malaysia

      JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    15. Yao, TW; Zeng, S; Wang, TW; Chen, SQ
      Phenotype analysis of cytochrome P4502C19 in Chinese subjects with mephenytoin S/R enantiomeric ratio in urine measured by chiral GC

      BIOMEDICAL CHROMATOGRAPHY
    16. Horai, Y; Kimura, M; Furuie, H; Matsuguma, K; Irie, S; Koga, Y; Nagahama, T; Murakami, M; Matsui, T; Yao, T; Urae, A; Ishizaki, T
      Pharmacodynamic effects and kinetic disposition of rabeprazole in relationto CYP2C19 genotypes

      ALIMENTARY PHARMACOLOGY & THERAPEUTICS
    17. Lam, LCW; Garcia-Barcelo, MM; Ungvari, GS; Tang, WK; Lam, VKL; Kwong, SL; Lau, BST; Kwong, PPK; Waye, MMY; Chiu, HFK
      Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients

      PHARMACOPSYCHIATRY
    18. Hadama, A; Ieiri, I; Morita, T; Kimura, M; Urae, A; Irie, S; Kaneda, T; Mamiya, K; Tashiro, N; Higuchi, S; Otsubo, K
      P-hydroxylation of phenobarbital: Relationship to (s)-mephenytoin hydroxylation (CYP2C19) polymorphism

      THERAPEUTIC DRUG MONITORING
    19. Venkatakrishnan, K; von Moltke, LL; Greenblatt, DJ
      Human drug metabolism and the cytochromes P450: Application and relevance of in vitro models

      JOURNAL OF CLINICAL PHARMACOLOGY
    20. Ingelman-Sundberg, M
      Implications of polymorphic cytochrome P450-dependent drug metabolism for drug development

      DRUG METABOLISM AND DISPOSITION
    21. Gerbal-Chaloin, S; Pascussi, JM; Pichard-Garcia, L; Daujat, M; Waechter, F; Fabre, JM; Carrere, N; Maurel, P
      Induction of CYP2C genes in human hepatocytes in primary culture

      DRUG METABOLISM AND DISPOSITION
    22. Obach, RS; Zhang, QY; Dunbar, D; Kaminsky, LS
      Metabolic characterization of the major human small intestinal cytochrome P450S

      DRUG METABOLISM AND DISPOSITION
    23. Kosuge, K; Jun, Y; Watanabe, H; Kimura, M; Nishimoto, M; Ishizaki, T; Ohashi, K
      Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamicsof diazepam in relation to CYP2C19 genotype status

      DRUG METABOLISM AND DISPOSITION
    24. Furuta, S; Kamada, E; Suzuki, T; Sugimoto, T; Kawabata, Y; Shinozaki, Y; Sano, H
      Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole

      XENOBIOTICA
    25. Laine, K; Anttila, M; Nyman, L; Wahlberg, A; Bertilsson, L
      CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    26. Furuta, T; Shirai, N; Xiao, F; Ohashi, K; Ishizaki, T
      Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    27. Wang, JH; Liu, ZQ; Wang, W; Chen, XP; Shu, Y; He, N; Zhou, HH
      Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    28. Yu, KS; Yim, DS; Cho, JY; Park, SS; Park, JY; Lee, KH; Jang, IJ; Yi, SY; Bae, KS; Shin, SG
      Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    29. Furuta, T; Shirai, N; Takashima, M; Xiao, F; Hanai, H; Sugimura, H; Ohashi, K; Ishizaki, T; Kaneko, E
      Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    30. Ha-Duong, NT; Dijols, S; Macherey, AC; Goldstein, JA; Dansette, PM; Mansuy, D
      Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P4502C19

      BIOCHEMISTRY
    31. Kirchheiner, J; Brosen, K; Dahl, ML; Gram, LF; Kasper, S; Roots, I; Sjoqvist, F; Spina, E; Brockmoller, J
      CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

      ACTA PSYCHIATRICA SCANDINAVICA
    32. Zhou, HH; Liu, ZO
      Ethnic differences in drug metabolism

      CLINICAL CHEMISTRY AND LABORATORY MEDICINE
    33. Salsali, M; Coutts, RT; Baker, GB
      A rapid electron-capture gas chromatographic procedure for the analysis ofp-hydroxymephenytoin

      JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
    34. Flockhart, DA; Oesterheld, JR
      Cytochrome P450-mediated drug interactions

      CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA
    35. Thijssen, HHW; Verkooijen, IWC; Frank, HLL
      The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol

      PHARMACOGENETICS
    36. Roddam, PL; Rollinson, S; Kane, E; Roman, E; Moorman, A; Cartwright, R; Morgan, GJ
      Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia

      PHARMACOGENETICS
    37. Streetman, DS; Bertino, JS; Nafziger, AN
      Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes

      PHARMACOGENETICS
    38. Gaedigk, A
      Interethnic differences of drug-metabolizing enzymes

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    39. Niwa, T; Tsutsui, M; Kishimoto, K; Yabusaki, Y; Ishibashi, F; Katagiri, M
      Inhibition of drug-metabolizing enzyme activity in human hepatic cytochrome P450s by bisphenol A

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    40. Hiratsuka, M; Agatsuma, Y; Omori, F; Narahara, K; Inoue, T; Kishikawa, Y; Mizugaki, M
      High throughput detection of drug-metabolizing enzyme polymorphisms by allele-specific fluorogenic 5 ' nuclease chain reaction assay

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    41. Wang, XY; Levy, RH; Ho, RJY
      Development of a semi-quantitative assay to detect full-length CYP2C19 RNA

      BIOTECHNIQUES
    42. Klotz, U
      Pharmacokinetic considerations in the eradication of Helicobacter pylori

      CLINICAL PHARMACOKINETICS
    43. Khaliq, Y; Gallicano, K; Seguin, I; Fyke, K; Carignan, G; Bulman, D; Badley, A; Cameron, DW
      Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    44. Tassaneeyakul, W; Tassaneeyakul, W; Vannaprasaht, S; Yamazoe, Y
      Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    45. Ismail, R; Hussein, A; Teh, LK; Isa, MN
      CYP2D6 phenotypes among Malays in Malaysia

      JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    46. Poolsup, N; Po, ALW; Knight, TL
      Pharmacogenetics and psychopharmacotherapy

      JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    47. Sagar, M; Bertilsson, L; Stridsberg, M; Kjellin, A; Mardh, S; Seensalu, R
      Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders

      ALIMENTARY PHARMACOLOGY & THERAPEUTICS
    48. Adachi, K; Katsube, T; Kawamura, A; Takashima, T; Yuki, M; Amano, K; Ishihara, S; Fukuda, R; Watanabe, M; Kinoshita, Y
      CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole

      ALIMENTARY PHARMACOLOGY & THERAPEUTICS
    49. Egan, LJ; Murray, JA
      New perspectives in gastric acid suppression: Genetic polymorphisms predict the efficacy of proton pump inhibitors

      DIGESTIVE DISEASES
    50. Shu, Y; Wang, LS; Xiao, WM; Wang, W; Huang, SL; Zhou, HH
      Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulphone

      ACTA PHARMACOLOGICA SINICA
    51. Shu, Y; Zhou, HH
      Individual and ethnic differences in CYP2C19 activity in Chinese populations

      ACTA PHARMACOLOGICA SINICA
    52. Eap, CB; Bertel-Laubscher, R; Zullino, D; Amey, M; Baumann, P
      Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: A case report

      PHARMACOPSYCHIATRY
    53. Houston, JB; Kenworthy, KE
      In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model

      DRUG METABOLISM AND DISPOSITION
    54. Wester, MR; Lasker, JM; Johnson, EF; Raucy, JL
      CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes

      DRUG METABOLISM AND DISPOSITION
    55. McGinnity, DF; Parker, AJ; Soars, M; Riley, RJ
      Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s

      DRUG METABOLISM AND DISPOSITION
    56. Renwick, AB; Surry, D; Price, RJ; Lake, BG; Evans, DC
      Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms

      XENOBIOTICA
    57. Wedlund, PJ
      The CYP2C19 enzyme polymorphism

      PHARMACOLOGY
    58. Fukuda, T; Nishida, Y; Zhou, Q; Yamamoto, I; Kondo, S; Azuma, J
      The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    59. Mamiya, K; Hadama, A; Yukawa, E; Ieiri, I; Otsubo, K; Ninomiya, H; Tashiro, N; Higuchi, S
      CYP2C19 polymorphism effect on phenobarbitone - Pharmacokineties in Japanese patients with epilepsy: analysis by population pharmacokinetics

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    60. Shu, Y; Wang, LS; Xu, ZH; He, N; Xiao, WM; Wang, W; Huang, SL; Zhou, HH
      5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    61. Sagar, M; Tybring, G; Dahl, ML; Bertilsson, L; Seensalu, R
      Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism

      GASTROENTEROLOGY
    62. Streetman, DS; Bleakley, JF; Kim, JS; Nafziger, AN; Leeder, JS; Gaedigk, A; Gotschall, R; Kearns, GL; Bertino, JS
      Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail"

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    63. Branch, RA; Adedoyin, A; Frye, RF; Wilson, JW; Romkes, M
      In vivo modulation of CYP enzymes by quinidine and rifampin

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    64. Lamba, JK; Dhiman, RK; Kohli, KK
      CYP2C19 genetic mutations in North Indians

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    65. Laine, K; Tybring, G; Bertilsson, L
      No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    66. Herrlin, K; Massele, AY; Rimoy, G; Alm, C; Rais, M; Ericsson, O; Bertilsson, L; Gustafsson, LL
      Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    67. Furuta, T; Takashima, M; Shirai, N; Xiao, F; Hanai, H; Ohashi, K; Ishizaki, T
      Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    68. Yoon, YR; Cha, IJ; Shon, JH; Lim, KA; Cha, YN; Jang, IJ; Park, CW; Shin, SG; Flockhart, DA; Shin, JG
      Relationship of paroxetine disposition to metoprolol metabolic ratio and CPsi P2D6*10 genotype of Korean subjects

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    69. Ho, SL; Kung, MHW; Li, LSW; Lauder, IJ; Ramsden, DB
      Cytochrome P4502D6 (debrisoquine 4-hydroxylase) and Parkinson's disease inChinese and Caucasians

      EUROPEAN JOURNAL OF NEUROLOGY
    70. Linder, MW; Valdes, R
      Pharmacogenetics in the practice of laboratory medicine

      MOLECULAR DIAGNOSIS
    71. Wennerholm, A; Johansson, I; Massele, AY; Jande, M; Alm, C; Aden-Abdi, Y; Dahl, ML; Ingelman-Sundberg, M; Bertilsson, L; Gustafsson, LL
      Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype

      PHARMACOGENETICS
    72. Xie, HG; Stein, CM; Kim, RB; Wilkinson, GR; Flockhart, DA; Wood, AJJ
      Allelic, genotypic and phenotypic distributions of S-mephenytoin 4 '-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world

      PHARMACOGENETICS
    73. Kaneko, A; Lum, JK; Yaviong, J; Takahashi, N; Ishizaki, T; Bertilsson, L; Kobayakawa, T; Bjorkman, A
      High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands

      PHARMACOGENETICS
    74. Kaneko, A; Bergqvist, Y; Taleo, G; Kobayakawa, T; Ishizaki, T; Bjorkman, A
      Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations

      PHARMACOGENETICS
    75. Griese, EU; Lapple, F; Eichelbaum, M
      Detection of CYP2C19 alleles*1,*2 and*3 by multiplex polymerase chain reaction

      PHARMACOGENETICS
    76. Rost, KL; Fuhr, U; Thomsen, T; Zaigler, M; Brockmoller, J; Bohnemeier, H; Roots, I
      Omeprazole weakly inhibits CYP1A2 activity in man

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    77. Masa, K; Arimori, K; Nakayama, T; Miyamoto, S; Fujii, J; Nakano, M
      Effect of clarithromycin and other macrolides on the sulfoxidation and 5-hydroxylation of lansoprazole in dogs

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    78. Damkier, P; Hansen, LL; Brosen, K
      Rifampicin treatment greatly increases the apparent oral clearance of quinidine

      PHARMACOLOGY & TOXICOLOGY
    79. Payne, VA; Chang, YT; Loew, GH
      Homology modeling and substrate binding study of human CYP2C9 enzyme

      PROTEINS-STRUCTURE FUNCTION AND GENETICS
    80. Payne, VA; Chang, YT; Loew, GH
      Homology modeling and substrate binding study of human CYP2C18 and CYP2C19enzymes

      PROTEINS-STRUCTURE FUNCTION AND GENETICS
    81. Mihara, K; Svensson, USH; Tybring, G; Hai, TN; Bertilsson, L; Ashton, M
      Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19

      FUNDAMENTAL & CLINICAL PHARMACOLOGY
    82. Bathum, L; Skjelbo, E; Mutabingwa, TK; Madsen, H; Horder, M; Brosen, K
      Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    83. Xie, HG; Kim, RB; Stein, CM; Wilkinson, GR; Wood, AJJ
      Genetic polymorphism of (S)-mephenytoin 4 '-hydroxylation in populations of African descent

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    84. Aynacioglu, AS; Brockmoller, J; Bauer, S; Sachse, C; Guzelbey, P; Ongen, Z; Nacak, M; Roots, I
      Frequency of cytochrome P450CYP2C9 variants in a Turkish population and functional relevance for phenytoin

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    85. Coller, JK; Somogyi, AA; Bochner, F
      Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    86. Brynne, N; Bottiger, Y; Hallen, B; Bertilsson, L
      Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    87. Kimura, M; Ieiri, I; Wada, Y; Mamiya, K; Urae, A; Iimori, E; Sakai, T; Otsubo, K; Higuchi, S
      Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping:possible effect of age, liver disease and length of therapy

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    88. Cohen, LG; Prince, J; Biederman, J; Wilens, T; Faraone, SV; Whitt, S; Mick, E; Spencer, T; Meyer, MC; Polisner, D; Flood, JG
      Absence of effect of stimulants on the pharmacokinetics of desipramine in children

      PHARMACOTHERAPY
    89. Coutts, RT; Urichuk, LJ
      Polymorphic cytochromes P450 and drugs used in psychiatry

      CELLULAR AND MOLECULAR NEUROBIOLOGY
    90. Shimoda, K; Jerling, M; Bottiger, Y; Yasuda, S; Morita, S; Bertilsson, L
      Pronounced differences in the disposition of clomipramine between Japaneseand Swedish patients

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    91. Tanaka, E
      Update: genetic polymorphism of drug metabolizing enzymes in humans

      JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    92. Tanaka, E
      Clinically significant pharmacokinetic drug interactions with benzodiazepines

      JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    93. Tanaka, E
      Clinically significant pharmacokinetic drug interactions between antiepileptic drugs

      JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    94. Tanaka, E; Hisawa, S
      Clinically significant pharmacokinetic drug interactions with psychoactivedrugs: antidepressants and antipsychotics and the cytochrome P450 system

      JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    95. Sagar, M; Janczewska, I; Ljungdahl, A; Bertilsson, L; Seensalu, R
      Effect of CYP2C19 polymorphism on serum levels of vitamin B-12 in patientson long-term omeprazole treatment

      ALIMENTARY PHARMACOLOGY & THERAPEUTICS
    96. Lew, EA
      Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy

      ALIMENTARY PHARMACOLOGY & THERAPEUTICS
    97. Ishizaki, T; Horai, Y
      Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole

      ALIMENTARY PHARMACOLOGY & THERAPEUTICS
    98. Kovacs, P; Edwards, DJ; Lalka, D; Scheiwe, WM; Stoeckel, K
      High-dose omeprazole: Use of a multiple-dose study design to assess bioequivalence and accuracy of CYP2C19 phenotyping

      THERAPEUTIC DRUG MONITORING
    99. Kobayashi, K; Ishizuka, T; Shimada, N; Yoshimura, Y; Kamijima, K; Chiba, K
      Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro

      DRUG METABOLISM AND DISPOSITION
    100. Nakajima, M; Nakamura, S; Tokudome, S; Shimada, N; Yamazaki, H; Yokoi, T
      Azelastine N-demethylation by cytochrome P-450 (CYP) 3A4, CYP2D6, and CYP1A2 in human liver microsomes: Evaluation of approach to predict the contribution of multiple CYPS

      DRUG METABOLISM AND DISPOSITION


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/12/19 alle ore 04:18:12